230 related articles for article (PubMed ID: 26284334)
1. ADAM10: a new player in breast cancer progression?
Mullooly M; McGowan PM; Kennedy SA; Madden SF; Crown J; O' Donovan N; Duffy MJ
Br J Cancer; 2015 Sep; 113(6):945-51. PubMed ID: 26284334
[TBL] [Abstract][Full Text] [Related]
2. Improved synthesis of ADAM10 inhibitor GI254023X.
Hoettecke N; Ludwig A; Foro S; Schmidt B
Neurodegener Dis; 2010; 7(4):232-8. PubMed ID: 20197648
[TBL] [Abstract][Full Text] [Related]
3. ADAM10 overexpression in human non-small cell lung cancer correlates with cell migration and invasion through the activation of the Notch1 signaling pathway.
Guo J; He L; Yuan P; Wang P; Lu Y; Tong F; Wang Y; Yin Y; Tian J; Sun J
Oncol Rep; 2012 Nov; 28(5):1709-18. PubMed ID: 22940701
[TBL] [Abstract][Full Text] [Related]
4. ADAM10 as a target for anti-cancer therapy.
Moss ML; Stoeck A; Yan W; Dempsey PJ
Curr Pharm Biotechnol; 2008 Feb; 9(1):2-8. PubMed ID: 18289051
[TBL] [Abstract][Full Text] [Related]
5. Proteolytic cleavage of amyloid precursor protein by ADAM10 mediates proliferation and migration in breast cancer.
Tsang JYS; Lee MA; Chan TH; Li J; Ni YB; Shao Y; Chan SK; Cheungc SY; Lau KF; Tse GMK
EBioMedicine; 2018 Dec; 38():89-99. PubMed ID: 30470613
[TBL] [Abstract][Full Text] [Related]
6. Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and β-catenin signaling.
Woods N; Trevino J; Coppola D; Chellappan S; Yang S; Padmanabhan J
Oncotarget; 2015 Nov; 6(34):35931-48. PubMed ID: 26440150
[TBL] [Abstract][Full Text] [Related]
7. miR-365 inhibits cell invasion and migration of triple negative breast cancer through ADAM10.
Liu F; Zhuang L; Wu R; Li D
J BUON; 2019; 24(5):1905-1912. PubMed ID: 31786854
[TBL] [Abstract][Full Text] [Related]
8. Cell migration in response to the amino-terminal fragment of urokinase requires epidermal growth factor receptor activation through an ADAM-mediated mechanism.
Bakken AM; Protack CD; Roztocil E; Nicholl SM; Davies MG
J Vasc Surg; 2009 May; 49(5):1296-303. PubMed ID: 19394555
[TBL] [Abstract][Full Text] [Related]
9. ADAM10 is overexpressed in human hepatocellular carcinoma and contributes to the proliferation, invasion and migration of HepG2 cells.
Yuan S; Lei S; Wu S
Oncol Rep; 2013 Oct; 30(4):1715-22. PubMed ID: 23912592
[TBL] [Abstract][Full Text] [Related]
10. ADAM10 promotes pituitary adenoma cell migration by regulating cleavage of CD44 and L1.
Pan Y; Han C; Wang C; Hu G; Luo C; Gan X; Zhang F; Lu Y; Ding X
J Mol Endocrinol; 2012 Aug; 49(1):21-33. PubMed ID: 22586143
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal effects between microRNA-140-5p and ADAM10 suppress migration and invasion of human tongue cancer cells.
Kai Y; Peng W; Ling W; Jiebing H; Zhuan B
Biochem Biophys Res Commun; 2014 Jun; 448(3):308-14. PubMed ID: 24530397
[TBL] [Abstract][Full Text] [Related]
12. ADAM10 is upregulated in melanoma metastasis compared with primary melanoma.
Lee SB; Schramme A; Doberstein K; Dummer R; Abdel-Bakky MS; Keller S; Altevogt P; Oh ST; Reichrath J; Oxmann D; Pfeilschifter J; Mihic-Probst D; Gutwein P
J Invest Dermatol; 2010 Mar; 130(3):763-73. PubMed ID: 19865098
[TBL] [Abstract][Full Text] [Related]
13. Suppression of tunicamycin-induced CD44v6 ectodomain shedding and apoptosis is correlated with temporal expression patterns of active ADAM10, MMP-9 and MMP-13 proteins in Caki-2 renal carcinoma cells.
Kim YH; Jung JC
Oncol Rep; 2012 Nov; 28(5):1869-74. PubMed ID: 22923171
[TBL] [Abstract][Full Text] [Related]
14. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of amyloid precursor protein processing enhances gemcitabine-mediated cytotoxicity in pancreatic cancer cells.
Woods NK; Padmanabhan J
J Biol Chem; 2013 Oct; 288(42):30114-30124. PubMed ID: 24022491
[TBL] [Abstract][Full Text] [Related]
16. EGF promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells.
Grabowska MM; Sandhu B; Day ML
Cell Signal; 2012 Feb; 24(2):532-538. PubMed ID: 22024284
[TBL] [Abstract][Full Text] [Related]
17. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.
Kohga K; Takehara T; Tatsumi T; Miyagi T; Ishida H; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N
Cancer Res; 2009 Oct; 69(20):8050-7. PubMed ID: 19826051
[TBL] [Abstract][Full Text] [Related]
18. ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro.
Eichenauer DA; Simhadri VL; von Strandmann EP; Ludwig A; Matthews V; Reiners KS; von Tresckow B; Saftig P; Rose-John S; Engert A; Hansen HP
Cancer Res; 2007 Jan; 67(1):332-8. PubMed ID: 17210715
[TBL] [Abstract][Full Text] [Related]
19. Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17.
Buchanan PC; Boylan KLM; Walcheck B; Heinze R; Geller MA; Argenta PA; Skubitz APN
J Biol Chem; 2017 Apr; 292(15):6339-6351. PubMed ID: 28232483
[TBL] [Abstract][Full Text] [Related]
20. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells.
Liu PC; Liu X; Li Y; Covington M; Wynn R; Huber R; Hillman M; Yang G; Ellis D; Marando C; Katiyar K; Bradley J; Abremski K; Stow M; Rupar M; Zhuo J; Li YL; Lin Q; Burns D; Xu M; Zhang C; Qian DQ; He C; Sharief V; Weng L; Agrios C; Shi E; Metcalf B; Newton R; Friedman S; Yao W; Scherle P; Hollis G; Burn TC
Cancer Biol Ther; 2006 Jun; 5(6):657-64. PubMed ID: 16627989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
